KR101559202B1 - 수용성 공액 고분자 나노입자의 제조방법 - Google Patents
수용성 공액 고분자 나노입자의 제조방법 Download PDFInfo
- Publication number
- KR101559202B1 KR101559202B1 KR1020130086636A KR20130086636A KR101559202B1 KR 101559202 B1 KR101559202 B1 KR 101559202B1 KR 1020130086636 A KR1020130086636 A KR 1020130086636A KR 20130086636 A KR20130086636 A KR 20130086636A KR 101559202 B1 KR101559202 B1 KR 101559202B1
- Authority
- KR
- South Korea
- Prior art keywords
- nanoparticles
- cancer
- conjugated polymer
- water
- polyaniline
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 124
- 238000000034 method Methods 0.000 title claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 229920001940 conductive polymer Polymers 0.000 title description 2
- 229920000547 conjugated polymer Polymers 0.000 claims abstract description 72
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 229920000642 polymer Polymers 0.000 claims abstract description 21
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 229920000767 polyaniline Polymers 0.000 claims description 62
- 230000008859 change Effects 0.000 claims description 30
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 239000004310 lactic acid Substances 0.000 claims description 13
- 235000014655 lactic acid Nutrition 0.000 claims description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 229940107700 pyruvic acid Drugs 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- -1 poly (1,4-phenylenevinylene) Polymers 0.000 claims description 5
- WUCWJXGMSXTDAV-QKMCSOCLSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-6-(6-cyclohexylhexoxy)-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@@H](OCCCCCCC2CCCCC2)[C@H](O)[C@H]1O WUCWJXGMSXTDAV-QKMCSOCLSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 229920001197 polyacetylene Polymers 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- ZWEVPYNPHSPIFU-AUGHYPCGSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-n-[3-[3-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl-[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenan Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@@H](O)C1 ZWEVPYNPHSPIFU-AUGHYPCGSA-N 0.000 claims description 2
- WXUWOACRYZHYQL-LJIZCISZSA-N (2s,3r,4s,5s,6r)-2-decylsulfanyl-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WXUWOACRYZHYQL-LJIZCISZSA-N 0.000 claims description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- SIDULKZCBGMXJL-UHFFFAOYSA-N 1-dimethylphosphoryldodecane Chemical compound CCCCCCCCCCCCP(C)(C)=O SIDULKZCBGMXJL-UHFFFAOYSA-N 0.000 claims description 2
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 claims description 2
- BLXVTZPGEOGTGG-UHFFFAOYSA-N 2-[2-(4-nonylphenoxy)ethoxy]ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCOCCO)C=C1 BLXVTZPGEOGTGG-UHFFFAOYSA-N 0.000 claims description 2
- HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 claims description 2
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 229920000488 Poly(1,4-phenylene sulfide) Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 241001092473 Quillaja Species 0.000 claims description 2
- 235000009001 Quillaja saponaria Nutrition 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 229920004929 Triton X-114 Polymers 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 239000002280 amphoteric surfactant Substances 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- GSVLCKASFMVUSW-UHFFFAOYSA-N decyl(dimethyl)phosphine oxide Chemical compound CCCCCCCCCCP(C)(C)=O GSVLCKASFMVUSW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004132 diethyl ether Drugs 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- JRFKIOFLCXKVOT-UHFFFAOYSA-N hydroxymethylnicotinamide Chemical compound OCNC(=O)C1=CC=CN=C1 JRFKIOFLCXKVOT-UHFFFAOYSA-N 0.000 claims description 2
- 229950005422 hydroxymethylnicotinamide Drugs 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 claims description 2
- CGVLVOOFCGWBCS-RGDJUOJXSA-N n-octyl β-d-thioglucopyranoside Chemical compound CCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CGVLVOOFCGWBCS-RGDJUOJXSA-N 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229920000128 polypyrrole Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920000123 polythiophene Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 claims 1
- 239000013504 Triton X-100 Substances 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims 1
- GCRLIVCNZWDCDE-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)nonanamide Chemical compound CCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO GCRLIVCNZWDCDE-UHFFFAOYSA-N 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 claims 1
- 229940073455 tetraethylammonium hydroxide Drugs 0.000 claims 1
- LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 7
- 239000000084 colloidal system Substances 0.000 abstract description 2
- 229920000775 emeraldine polymer Polymers 0.000 description 25
- 238000002835 absorbance Methods 0.000 description 23
- 239000002019 doping agent Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 238000000935 solvent evaporation Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940076788 pyruvate Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000004776 molecular orbital Methods 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- GTQCHJYVKDXMRU-YMEALESQSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-6-hexadecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GTQCHJYVKDXMRU-YMEALESQSA-N 0.000 description 1
- PITRRWWILGYENJ-UHFFFAOYSA-N 2-[2-[2-[2-[2-(4-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCO)C=C1 PITRRWWILGYENJ-UHFFFAOYSA-N 0.000 description 1
- UYEMNFYVTFDKRG-UHFFFAOYSA-N 2-[4,5-dihydroxy-2-(hydroxymethyl)-6-undecoxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC1C(O)C(OCCCCCCCCCCC)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 UYEMNFYVTFDKRG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101001074945 Homo sapiens PILR alpha-associated neural protein Proteins 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 102100035983 PILR alpha-associated neural protein Human genes 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- RVTGFZGNOSKUDA-ZNGNCRBCSA-N cyclohexyl-pentyl-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@@H](OCCCCCC2CCCCC2)[C@H](O)[C@H]1O RVTGFZGNOSKUDA-ZNGNCRBCSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- OJSUWTDDXLCUFR-YVKIRAPASA-N deoxy-bigchap Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@H](O)C1 OJSUWTDDXLCUFR-YVKIRAPASA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- DSDVUXRTYBTVRN-UHFFFAOYSA-N dimethyl(tetradecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCC[NH+](C)C DSDVUXRTYBTVRN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000011263 electroactive material Substances 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000010335 redox stress Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
- C08J3/126—Polymer particles coated by polymer, e.g. core shell structures
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
도 2는 용매 교환법에 따른 수용성 공액 고분자 나노입자의 제조방법의 모식도이다.
도 3은 용매 교환법에 따른 수용성 공액 고분자 나노입자의 특성을 분석한 결과이다. a)는 폴리아닐린 함량에 따른 나노입자의 크기 변화, b)는 10mg의 폴리아닐린이 함유된 나노입자의 TEM 이미지(스케일 바: 100nm), c)는 폴리아닐린 분말(bare PAni), 트윈 80 및 TPAni의 FT-IR 스펙트럼을 보여준다.
도 4는 양친매성 화합물의 함량(트윈 80으로서 0mg, 10mg, 50mg, 100mg, 200mg, 400mg 및 500mg) 에 따른 10mg의 폴리아닐린이 함유된 공액 고분자 나노입자의 크기 변화를 보여준다.
도 5는 공액 고분자 자체와 용매 교환법으로 제조된 수용성 공액 고분자 나노입자의 다양한 용매에 대한 용해도 실험 결과이다. a)는 폴리아닐린 분말의 NMP(N-methyl pyrrolidone), CF(chloroform) 및 DW(deionized water)에 대한 용해도, b)는 수용성 폴리아닐린 나노입자(0.05mg/㎖)의 물 및 CF에 대한 용해도, c)는 수용성 폴리아닐린 나노입자(0.05mg/㎖)의 물 및 NMP에 대한 용해도를 보여준다.
도 6은 용매 증발법에 의해 제조된 수용성 공액 고분자 나노입자의 특성을 실험한 결과이다. a)는 클로로포름(하부층) 및 물(상부층)에서 폴리아닐린 나노입자(Emeraldine Base Polyaniline nanoparticle, EBPANP)(왼쪽) 및 폴리아닐린 분말(에머랄딘 염기; EB)(오른쪽)의 분산성 실험, b)는 폴리아닐린 나노입자의 SEM 이미지(스케일 바: 200 nm), c)는 폴리아닐린 나노입자의 크기 분포를 보여준다.
도 7은 용매 증발법에 따라 제조된 수용성 공액 고분자 나노입자의 공액 고분자 함량에 따른 크기 변화를 나타낸다.
도 8은 다양한 농도의 HCl에 따른 수용성 공액 고분자 나노입자의 색 변화 효과를 실험한 결과이다. a)는 육안으로 색 변화를 관찰한 것이고, b)는 흡광도, c) 흡광도 비를 나타낸다.
도 9는 다양한 생물학적 도펀트(젖산, 피루브산, NaCl, FBS)에 의한 수용성 공액 고분자 나노입자의 색 변화 효과를 흡광도 및 흡광도 비를 통해서 실험한 결과를 보여준다.
도 10은 암 세포의 상태(살아있는 경우, 고정된 경우, 용해된 경우)에 따른 수용성 공액 고분자 나노입자의 색 변화 효과를 실험한 결과를 보여준다. a)는 육안 관찰 결과, b)는 흡광도, c)는 흡광도 비의 변화를 나타낸다.
Claims (13)
- 물 및 양친매성 고분자의 혼합물과 수성 용매 및 공액 고분자의 혼합물을 접촉시키는 것을 포함하고,
상기 양친매성 고분자는 양이온성 계면활성제, 음이온성 계면활성제, 양쪽성 계면활성제, 비이온성 계면활성제 또는 이들의 혼합물이며,
상기 공액 고분자는 폴리아세틸렌(polyacetylene), 폴리아닐린(polyaniline), 폴리피롤(polypyrrole), 폴리티오펜(polythiophene), 폴리(1,4-페닐렌비닐렌)(poly(1,4-phenylenevinylene)), 폴리(1,4-페닐렌설파이드)(poly(1,4-phenylenesulfide)), 폴리(플루오레닐렌에티닐렌)(poly(fluorenyleneethynylene)) 및 이들의 유도체로 이루어진 군으로부터 선택되는 하나 이상인 수용성 공액 고분자 나노입자의 제조방법.
- 제1항에 있어서,
접촉은 물 및 양친매성 고분자의 혼합물에 수성 용매 및 공액 고분자의 혼합물을 적가함으로써 이루어지는 수용성 공액 고분자 나노입자의 제조방법.
- 삭제
- 제1항에 있어서,
양친매성 고분자는 소듐 콜레이트 하이드레이트, n-옥틸글루코시드, 옥틸티오글루코시드, N-옥타노일-N-메틸글루카민, N-노나노일-N-메틸글루카민, 퀼라야 껍질(quillaja bark) 유래 사포닌, 폴리옥시에틸렌 소르비탄 모노라우레이트, 도데실 황산 나트륨, 테트라메틸암모늄 하이드록사이드 용액, 헥사데실트리메틸암모늄 브로마이드(CTAB), 디도데실디메틸암모늄 브로마이드(DMAB), N,N-비스(3-D-글루콘아미도프로필)데옥시콜아미드(deoxy-BIGCHAP), N,N-비스(3-D-글루콘아미도프로필)콜아미드(BIGCHAP), 폴리비닐알코올, 폴리에틸렌 글리콜 도데실 에테르, 플루로닉 F-68, 트리톤 X-100, 트리톤 X-114, 트윈 40, 이게팔(Igepal) CA-630, 이게팔 CO-210, 이게팔 CO-520, 이게팔 CO-630, 이게팔 CO-720, 이게팔 CO-890, 이게팔 DM-970, 이게팔 CA-210, 이게팔 CA-520, 이게팔 CA-630, N-데카노일-N-메틸글루카민, 노닐페닐-폴리에틸렌 글리콜, 브리지 76(Brij 76), 브리지 58, 브리지 30, 폴리소르베이트 80, 사이클로헥실메틸-β-D-말토시드 (Cymal-1), 2-사이클로헥실에틸-β-D-말토시드 (Cymal-2), 5-사이클로헥실펜틸-β-D-말토시드(Cymal-5), 6-사이클로헥실헥실-β-D-말토시드(Cymal-6), 디기토닌, 데실-β-D-말토피라노시드, 라우릴-β-D-말토시드(DDM), n-헥사데실-β-D-말토시드, 운데실-β-D-말토시드, 데실-β-D-1-티오말코피라노시드, 데실-β-D-1-티오글루코피라노시드, 디메틸데실포스핀 옥사이드, 도데실디메틸포스핀 옥사이드 및 이들의 혼합물로 이루어진 군으로부터 선택된 하나 이상인 수용성 공액 고분자 나노입자의 제조방법.
- 제1항에 있어서,
수성 용매는 아세톤, 아세토니트릴, 사염화탄소, 클로로포름, 사이클로헥산, 1,2-디클로로에탄, 디클로로메탄, 디에틸에테르, 디메틸 포름아마이드, 디메틸설폭사이드, 1,4-디옥산, 에탄올, 에틸 아세테이트, 헵탄, 헥산, 메탄올, 메틸 3급 부틸 에테르(methyl-tert-buryl ether), 펜탄, 1-프로판올, 2-프로판올, 테트라하이드로퓨란, 톨루엔, 2,2,4-트리메틸펜탄, 물 및 이들의 혼합물로 이루어진 군으로부터 선택된 하나 이상인 수용성 공액 고분자 나노입자의 제조방법.
- 삭제
- 제1항에 있어서,
공액 고분자 나노입자는 1nm 내지 500nm의 직경을 갖는 수용성 공액 고분자 나노입자의 제조방법.
- 제1항에 있어서,
공액 고분자 나노입자는 1nm 내지 100nm의 직경을 갖는 수용성 공액 고분자 나노입자의 제조방법.
- 제1항에 있어서,
pH; 활성산소종, 활성질소종, 과산화 수소, 생체 이온 및 프리 라디칼로 이루어진 군으로부터 선택된 하나 이상의 산화물질; 또는, 산화환원력을 갖는 생체 분자 중 적어도 하나에 의한 고분자의 도핑에 의해 색의 변화를 나타내는 수용성 공액 고분자 나노입자의 제조방법.
- 제9항에 있어서,
산화환원력을 갖는 생체 분자는 피루브산 또는 젖산인 수용성 공액 고분자 나노입자의 제조방법.
- 삭제
- 제1항, 제2항, 제4항, 제5항 및 제7항 내지 제10항 중 어느 한 항에 따라 제조된 암세포 판별용 수용성 공액 고분자 나노입자.
- 제12항에 있어서, 암세포는 직장암, 담낭암, 난소암, 대장암, 임파종, 뇌암, 전립선암, 악성흑색종, 유방암, 위암, 폐암, 난소암, 간암, 기관지암, 비인두암, 후두암, 췌장암, 방광암, 결장암, 육종암 또는 자궁암인 수용성 공액 고분자 나노입자.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130086636A KR101559202B1 (ko) | 2013-07-23 | 2013-07-23 | 수용성 공액 고분자 나노입자의 제조방법 |
PCT/KR2013/011826 WO2015012455A1 (ko) | 2013-07-23 | 2013-12-18 | 수용성 공액 고분자 나노입자의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130086636A KR101559202B1 (ko) | 2013-07-23 | 2013-07-23 | 수용성 공액 고분자 나노입자의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150011869A KR20150011869A (ko) | 2015-02-03 |
KR101559202B1 true KR101559202B1 (ko) | 2015-10-15 |
Family
ID=52393465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130086636A KR101559202B1 (ko) | 2013-07-23 | 2013-07-23 | 수용성 공액 고분자 나노입자의 제조방법 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101559202B1 (ko) |
WO (1) | WO2015012455A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101597023B1 (ko) * | 2014-03-20 | 2016-02-24 | 연세대학교 산학협력단 | 공액 고분자 기반 유기나노켄처 및 이의 제조방법 |
CN111909386B (zh) * | 2020-07-16 | 2022-05-24 | 南京邮电大学 | 一种共轭聚合物-有机金属框架复合纳米材料及其制备方法 |
CN113499312A (zh) * | 2021-07-08 | 2021-10-15 | 扬州大学 | 超分子核壳复合物、超分子载药核壳复合物、二者的制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030129239A1 (en) | 2001-09-28 | 2003-07-10 | Rina Goldshtein | Water soluble nanoparticles of hydrophilic and hydrophobic active materials and an apparatus and method for their production |
JP2007297500A (ja) * | 2006-04-28 | 2007-11-15 | Achilles Corp | 導電性高分子微粒子分散体及びそれを用いる導電性塗料 |
KR101267313B1 (ko) | 2011-03-22 | 2013-05-27 | 연세대학교 산학협력단 | 유기 고분자 나노입자를 이용한 암세포의 광열치료법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009126571A2 (en) * | 2008-04-09 | 2009-10-15 | Cornell University | Nanoparticle-mediated microwave treatment methods |
WO2010124270A1 (en) * | 2009-04-24 | 2010-10-28 | Baker Christina O | Functionalized polymer biosensor |
-
2013
- 2013-07-23 KR KR1020130086636A patent/KR101559202B1/ko active IP Right Grant
- 2013-12-18 WO PCT/KR2013/011826 patent/WO2015012455A1/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030129239A1 (en) | 2001-09-28 | 2003-07-10 | Rina Goldshtein | Water soluble nanoparticles of hydrophilic and hydrophobic active materials and an apparatus and method for their production |
JP2007297500A (ja) * | 2006-04-28 | 2007-11-15 | Achilles Corp | 導電性高分子微粒子分散体及びそれを用いる導電性塗料 |
KR101267313B1 (ko) | 2011-03-22 | 2013-05-27 | 연세대학교 산학협력단 | 유기 고분자 나노입자를 이용한 암세포의 광열치료법 |
Also Published As
Publication number | Publication date |
---|---|
KR20150011869A (ko) | 2015-02-03 |
WO2015012455A1 (ko) | 2015-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lü et al. | Synthesis and heavy‐metal‐ion sorption of pure sulfophenylenediamine copolymer nanoparticles with intrinsic conductivity and stability | |
Li et al. | Facile high‐yield synthesis of polyaniline nanosticks with intrinsic stability and electrical conductivity | |
Kinlen et al. | Emulsion polymerization process for organically soluble and electrically conducting polyaniline | |
Quintanilha et al. | The use of gum Arabic as “Green” stabilizer of poly (aniline) nanocomposites: A comprehensive study of spectroscopic, morphological and electrochemical properties | |
Wang et al. | Uniformly Shaped Poly (p‐phenylenediamine) Microparticles: Shape‐controlled Synthesis and Their Potential Application for the Removal of Lead Ions from Water | |
Somani | Synthesis and characterization of polyaniline dispersions | |
Song et al. | Synthesis of polyaniline/NiO nanobelts by a self-assembly process | |
Zhang et al. | Characterization of polyaniline nanotubes formed in the presence of amino acids | |
Lv et al. | Self-assembly and pH response of electroactive liquid core–tetra (aniline) shell microcapsules | |
Leng et al. | Wettability switching of SDS-doped polyaniline from hydrophobic to hydrophilic induced by alkaline/reduction reactions | |
Yu et al. | Titanium dioxide core/polymer shell hybrid composite particles prepared by two-step dispersion polymerization | |
Kuo et al. | Dispersible polyaniline nanoparticles in aqueous poly (styrenesulfonic acid) via the interfacial polymerization route | |
Alizadeh et al. | Soluble fluorescent polymeric nanoparticles based on pyrrole derivatives: synthesis, characterization and their structure dependent sensing properties | |
Han et al. | Preparation and characterization of polypyrrole–silica colloidal nanocomposites in water–methanol mixtures | |
US10864169B2 (en) | Conjugated polymer nanoparticles and manufacturing method thereof | |
Cruz-Silva et al. | Enzymatic synthesis of colloidal polyaniline particles | |
Mao et al. | pH-switched luminescence and sensing properties of a carbon dot–polyaniline composite | |
Dispenza et al. | Inherently fluorescent polyaniline nanoparticles in a dynamic landscape | |
KR101559202B1 (ko) | 수용성 공액 고분자 나노입자의 제조방법 | |
Shi et al. | The pH-controlled morphology transition of polyaniline from nanofibers to nanospheres | |
Cheng et al. | Morphology of polyaniline nanoparticles synthesized in triblock copolymers micelles | |
Taş et al. | The chemical synthesis and characterizations of silver-doped polyaniline: role of silver–solvent interactions | |
Pirhady Tavandashti et al. | Morphology transition control of polyaniline from nanotubes to nanospheres in a soft template method | |
US20140110636A1 (en) | Template-free aqueous synthesis of conductive polymer nanoparticles | |
Tan et al. | Template-free synthesis and characterization of single-phase voided poly (o-anisidine) and polyaniline colloidal spheres |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20130723 |
|
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20131218 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20130723 Comment text: Patent Application |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150311 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20150925 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20151002 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20151002 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20181001 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20181001 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20191002 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20191002 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20201005 Start annual number: 6 End annual number: 6 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20220713 |